Assessment of fetuin-A in patients with comorbidity of non-alcoholic fatty liver disease and arterial hypertension

Ass.prof. К.О. Prosolenko

Kharkiv National Medical University

The aim of our study was to investigate serum fetuin A levels in patients with NAFLD and its comorbidity with essential hypertension or renoparenchymal hypertension, as well as to evaluate the association of this indicator with the major pathogenetic factors of these diseases. All patients were divided into five groups: group I — patients with NAFLD (60 patients), group II — patients with comorbidity of NAFLD and essential hypertension (121 patients), group III — patients with comorbidity of NAFLD and renoparenchymal hypertension (88 patients), group IV — patients with essential hypertension (30 patients), group V — patients with renoparenchymal hypertension (30 patients). All patients had stage II, grade2 of hypertension. Patients’ age ranged from 18 to 66 years. The mean age of the patients was 49.12 ± 10.66 years. The control group consisted of 20 healthy individuals. Clinical examination of patients included evaluation of the parameters of objective examination: in particular anthropometric data and blood pressure by standard methods. Conducted abdominal ultrasound, vessels. In some patients, the Fibromax test was performed. The levels of ALT, insulin with determination of HOMA index, total cholesterol, adiponectin, cytokeratin-18, malondialdehyde, superoxidedismutase, tumor necrosis factor-α, fetuin A were determined.

In patients with NAFLD and various manifestations of metabolic syndrome, it has been found that, in the absence of diabetes mellitus and / or clinically pronounced atherosclerosis, an increase in fetuin A is associated with a degree of liver steatosis and not associated with liver fibrosis. Increase in fetuin A is more significant in groups with NAFLD comorbidity with essential hypertension and renoparenchymal hypertension, but is not associated with levels of SBP and DBP. This fact may indicate not a direct effect of essential hypertension and renoparenchymal hypertension on elevated levels of fetuin A, but this elevation can be associated with metabolic disorders that are more pronounced in the presence of comorbidity. In patients with NAFLD, regardless of the presence of its comorbidity with essential hypertension or renoparenchymal hypertension, there is an association of serum levels of fetuin A with hypoadectinemia and insulin resistance.The results of other studies were also analyzed, which were devoted to the study of the relationship of fetuin A with NAFLD, hypertension, atherosclerosis, CKD and others.

Key Words: non-alcoholic fatty liver disease, arterial hypertension, fetuin A, comorbidity.

https://dx.doi.org/10.15407/internalmed2019.02.083

Download.PDF

For citing:

  1. Просоленко, К.О. Оцінка показників фетуїну-А у пацієнтів з коморбідностю неалкогольної жирової хвороби печінки та артеріальної гіпертензії // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2019. – № 2. – С. 83-89. doi: 10.15407/internalmed2019.02.083
  2. Prosolenko KO. [Assessment Of Fetuin-A In Patients With Comorbidity Of Non-Alcoholic Fatty Liver Disease And Arterial Hypertension]. Shidnoevr. z. vnutr. simejnoi med. 2019;2:83-89. doi: 10.15407/internalmed2019.02.083. Ukrainian.

References:

1. Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;1:81-84. English. DOI: 10.1111/ liv.13299.
https://doi.org/10.1111/liv.13299

2. Brix JM, Stingl H, Höllerl F, Schernthaner GH, Kopp HP, Schernthane G. Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. Journal of Clinical Endocrinology and Metabolism. 2010;95:4877-4881. English. DOI: 10.1210/jc.2010-0148.
https://doi.org/10.1210/jc.2010-0148

3. Chen HY, Chiu YL, Hsu SP, Pai MF, Lai CF, Peng YS, Kao TW, Hung KY, Tsai TJ, Wu KD. Association of serum fetuin-A with truncal obesity and dyslipdemia in non-diabetic hemodialysis patients. European Journal of Endocrinology. 2009;160:777-783. English. DOI: 10.1530/eje-08-0813.
https://doi.org/10.1530/EJE-08-0813

4. Cui Z, Xuan R, Yang Y. Serum fetuin A level is associated with nonalcoholic fatty liver disease in Chinese population. Oncotarget. 2017;8:107149-107156. English. DOI: 10.18632/oncotarget.22361.
https://doi.org/10.18632/oncotarget.22361

5. Dabrowska AM, Tarach JS, Wojtysiak-Duma B, Duma D. Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature // Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159:352-359. English. DOI: 10.5507/bp.2015.018.
https://doi.org/10.5507/bp.2015.018

6. Dogru T, Genc H, Tapan S, Aslan F, Ercin CN, Ors F, Kara M, Sertoglu E, Karslioglu Y, Bagci S, Kurt I, Sonmez A. Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. Clinical Endocrinology (Oxf). 2013;78:712-717. DOI: 10.1111/j.13652265.2012.04460.x. English.
https://doi.org/10.1111/j.1365-2265.2012.04460.x

7. Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, Loberg EM, Haaland T, Konopski Z, Wium C, Aasheim ET, Johansen OE, Aukrust P, Halvorsen B, Birkeland KI. Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. European Journal of Endocrinology. 2012;166:503-510. English. DOI: 10.1530/eje-11-0864.
https://doi.org/10.1530/EJE-11-0864

8. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Haring HU, Stefan N. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. 2008;3:e1765. English. DOI: 10.1371/journal.pone.0001765.
https://doi.org/10.1371/journal.pone.0001765

9. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, Leunissen KML, Krediet RT, Dekker FW. Netherlands cooperative study on the adequacy of Dialysis (NECOSAD). Association of serum fetuin-A levels with mortality in dialysis patients. Kidney International. 2007;72:202-207. English. DOI: 10.1038/sj.ki.5002178.
https://doi.org/10.1038/sj.ki.5002178

10. Guarneri M, Geraci C, Incalcaterra F, Arsena R, Mulè G, Vaccaro F, Luna C, Cerasola G, Cottone S. Subclinical atherosclerosis and fetuin-A plasma levels in essential hypertensive patients. Hypertension Research. 2013;36:129-133. English. DOI: 10.1038/hr.2012.136.
https://doi.org/10.1038/hr.2012.136

11. Ismail NA, Ragab S, Abd El Dayem SM, Abd ElBaky A , Salah N, Hamed M, Assal H, Koura H. Fetuin-A levels in obesity: differences in relation to metabolic syndrome and correlation with clinical and laboratory variables. Archives of Medical Science. 2012;8:826-823. English. DOI: 10.5114/aoms.2012.31616.
https://doi.org/10.5114/aoms.2012.31616

12. Ix JH, Sharma K. Mechanism linking obesity, chronic kidney disease and fatty liver disease: the roles of fetuin-A, adiponectin and AMPK. Journal of the American Society of Nephrology. 2010;21:406-412. English. DOI: 10.1681/asn.2009080820.
https://doi.org/10.1681/ASN.2009080820

13. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation. 2006;113:1760-1767. English. DOI: 10.1161/circulationaha.105.588723.
https://doi.org/10.1161/CIRCULATIONAHA.105.588723

14. Kaushik SV, Plaisance EP, Kim T, Huang ЕY, Mahurin AJ, Grandjean PW, Mathews ST. Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome. Diabetes/Metabolism Research and Reviews. 2009;25:427-434. English. DOI: 10.1002/dmrr.967.
https://doi.org/10.1002/dmrr.967

15. Kettler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J. Association of low fetuin-A (AHSG) concentration in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. The Lancet. 2003;361:827-833. English. DOI: 10.1016/s0140-6736(03)12710-9.
https://doi.org/10.1016/S0140-6736(03)12710-9

16. Koch M, Jacobs G, Hampe J, Rosenstiel P, Krawczak M, Nöthlings U. Higher fetuin-A level is associated with coexistence of elevated alanine aminotransferase and the metabolic syndrome in the general population. Metabolic Syndrome and Related Disorders. 2013 Dec;11:377-384. English. DOI: 10.1089/met.2013.0078.
https://doi.org/10.1089/met.2013.0078

17. Lavebratt C, Wahlqvist S, Nordfors L, Hoffstedt J, Arner P. AHSG variant is associated with leaness among Swedish men. Hum Genet. 2005;117:54-60. English. DOI: 10.1007/s00439-005-1286-z.
https://doi.org/10.1007/s00439-005-1286-z

18. Lebensztejn DM, Białokoz-Kalinowska I, Kłusek-Oksiuta M, Tarasów E, Wojtkowska M, Kaczmarski M. Serum fetuin A concentration is elevated in children with non-alcoholic fatty liver disease. Adv Med Sci. 2014;59:81-4. English. DOI:10.1016/j.advms.2013.08.003.
https://doi.org/10.1016/j.advms.2013.08.003

19. Rametta R, Ruscica M, Dongiovanni P, Macchi C, Fracanzani AL, Steffani L, Fargion S, Magni P, Valenti L. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance. Eur J Clin Invest. 2014;44:627-33. English. DOI: 10.1111/eci.12280.
https://doi.org/10.1111/eci.12280

20. Reinehr T, Roth CL. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab. 2008;93(11):4479-85. English. DOI:10.1210/jc.2008-1505.
https://doi.org/10.1210/jc.2008-1505

21. Roos M, Oikonomou D, von Eynatten M, Luppa PB, Heemann U, Lutz J, Baumann M, Nawroth PP, Bierhaus A, Humpert PM. Associations of fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy. Cardiovasc Diabetol. 2010;9:48. English. DOI: 10.1186/1475-2840-9-48.
https://doi.org/10.1186/1475-2840-9-48

22. Sato M, Kamada Y, Takeda Y, Kida S, Ohara Y, Fujii H, Akita M, Mizutani K, Yoshida Y, Yamada M, Hougaku H, Takehara T, Miyoshi E. Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects. Liver Int. 2015;35(3):925-35. English. doi: 10.1111/liv.12478.
https://doi.org/10.1111/liv.12478

23. Singh M, Sharma PK, Garg VK, Mondal SC, Singh АK, Kumar N. Role of fetuin-A in atherosclerosis associated with diabetic patients. J Pharm Pharmacol. 2012;64(12):1703-8. English. DOI: 10.1111/j.2042-7158.2012.01561.x.
https://doi.org/10.1111/j.2042-7158.2012.01561.x

24. Stefan N, Hennige AM, Steiger H, Machann J, Schick F, Krober SM, Machicao F, Fritsche A, Haring HU. α2-Heremans-Schmid Glycoprotein/Fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care. 2006;29(4):853-7. English. DOI: 10.2337/diacare.29.04.06.dc05-1938.
https://doi.org/10.2337/diacare.29.04.06.dc05-1938

25. Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol. 2010;5:2166-71. English. doi: 10.2215/CJN.05050610.
https://doi.org/10.2215/CJN.05050610

26. Xu Y, Xu M, Bi Y, Song A, Huang Y, Liu Y, Wu Y, Chen Y, Wang W, Li X, Ning G. Serum fetuin-A is corretaled with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis. 2011;216(1):180-6. English. DOI: 10.1016/j.atherosclerosis.2011.01.020
https://doi.org/10.1016/j.atherosclerosis.2011.01.020

27. Yilmaz Y, Yonal O, Kurt R, Ari F, Oral AY, Celikel CA, Korkmaz S, Ulukaya E, Ozdogan O, Imeryuz N, Avsar E, Kalayci C. Serum fetuin A/α2HSglycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. Ann Clin Biochem. 2010;47:549-53. English. doi: 10.1258/acb.2010.010169.
https://doi.org/10.1258/acb.2010.010169